Abd El-Hameed, A., Abdelsalam, N., Saleh, A., Awad, A., ElShabrawy, A. (2022). COVID-19 associated mucormycosis and diabetes mellitus: An exploratory study. Microbes and Infectious Diseases, 3(2), 270-278. doi: 10.21608/mid.2022.122341.1248
Ayman R. Abd El-Hameed; Noha M. Abdelsalam; Alaa Mohamed Ahmed Saleh; Ali Mohammad Mohammad Awad; Arafa M. ElShabrawy. "COVID-19 associated mucormycosis and diabetes mellitus: An exploratory study". Microbes and Infectious Diseases, 3, 2, 2022, 270-278. doi: 10.21608/mid.2022.122341.1248
Abd El-Hameed, A., Abdelsalam, N., Saleh, A., Awad, A., ElShabrawy, A. (2022). 'COVID-19 associated mucormycosis and diabetes mellitus: An exploratory study', Microbes and Infectious Diseases, 3(2), pp. 270-278. doi: 10.21608/mid.2022.122341.1248
Abd El-Hameed, A., Abdelsalam, N., Saleh, A., Awad, A., ElShabrawy, A. COVID-19 associated mucormycosis and diabetes mellitus: An exploratory study. Microbes and Infectious Diseases, 2022; 3(2): 270-278. doi: 10.21608/mid.2022.122341.1248
COVID-19 associated mucormycosis and diabetes mellitus: An exploratory study
1Department of Internal Medicine, Faculty of Medicine, Zagazig University, Egypt
2Department of Community Medicine, Faculty of Medicine, Zagazig University, Egypt
3Department of Ophthalmology, Faculty of Medicine, Zagazig University, Egypt
4Department of Otorhinolaryngology, Faculty of Medicine, Zagazig University, Egypt
5Department of Internal medicine , Faculty of medicine, Zagazig University, Egypt
Abstract
Background:Mucormycosis has abruptly increased in Egypt during the third wave of COVID-19 especially in patients with diabetes mellitus (DM). The aim of this study was to investigate the risk factors, clinical presentation and outcome of mucormycosis in COVID-19 patients with diabetes. Methods: Prospective cohort study was conducted on 72 COVID-19 patients with DM presented with mucormycosis at intensive care units and Ear, Nose, and Throat Department of Zagazig University Hospitals over a period of three months from May 2021 to August 2021. All participants were submitted to history taking, examination, laboratory investigation, radiological and histopathology and culture testing. Results: Post COVID-19 new-onset diabetes mellitus (NOD) was detected in 40% of studied patients. 72.2% of patients had poorly controlled diabetes. Majority of studied patients presented by rhino-orbital mucormycosis (90.3%) and about 86% of them were operated. Hundred percent of patients gave history of antibiotic use and also nearly 99.0% of them received corticosteroids, while only 1.4% of them received tocilizumab. There was statistically significant association between operated patients, hemoglobin (HB) level, lymphocyte count, neutrophil-lymphocyte ratio (NLR), and CRP level with disease prognosis. Conclusions: Poorly controlled DM and steroid use are the most important risk for post COVID-19 mucormycosis. Early surgical intervention carried better disease outcome.